Roivant Sciences Ltd
ROIV
Company Profile
Business description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact
50 Broadway
7th Floor
LondonSW1H 0BD
GBRT: +44 2074003347
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
750
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,777.90 | 50.80 | -0.58% |
CAC 40 | 7,859.41 | 92.70 | 1.19% |
DAX 40 | 24,445.24 | 238.33 | 0.98% |
Dow JONES (US) | 44,240.76 | 165.60 | -0.37% |
FTSE 100 | 8,874.09 | 19.91 | 0.22% |
HKSE | 23,892.32 | 255.75 | -1.06% |
NASDAQ | 20,418.46 | 5.95 | 0.03% |
Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
S&P 500 | 6,225.52 | 4.46 | -0.07% |
S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
SSE Composite Index | 3,493.05 | 4.43 | -0.13% |